Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group
48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group
ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group
48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group
ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.